Language:
eu
es
en
Basque Research Elhuyar - Zientzia

BASQUE RESEARCH
 Basque research, development and innovation web site

Contact:
Laura Juampérez
Universidad de Navarra
Contact details:
ljuamperez@unav.es
(+34) 948 425600 ext. 6620
Universidad de Navarra

2010/9/14

Molecule identified that increases survival of stomach cancer patients

“The high presence of microRNA 451 enhances the response to treatment with chemo-radiotherapy and increases the survival of patients with stomach cancer”, explained Dr. Jesús García-Foncillas, chief researcher of the Pharmacogenomics Laboratory at the Applied Medical Research Centre (CIMA) and Director of Oncology at the University Hospital of Navarra. This was one of the results presented at the IV Congress of the Spanish Society for Pharmacogenetics and Pharmacogenomic, recently held at CIMA.

Pharmacogenetics studies the genetic bases determining the response of an individual to treatment, as well as possible toxic reactions; pharmacogenomics analyses the molecular and biological mechanisms involved in a disease in order to develop new medicines. “We know that variations in small molecules (microRNAs) give rise to different responses to the same pharmaceutical drug. In this line, a number of approaches are being made in clinical practice, such as the study of mutations of the K-RAS gene in cancer of the colon or of the EGFR in lung cancer, and which enable directing individualised treatment for each patient”.

The study presented at this scientific meeting analysed the role of microRNA 451 in stomach cancer, “Patients with a high expression of this molecule show greater survival rates, and so could be a biomarker for treatment response”. The CIMA researchers are also taking part in other trials, such as studies with the 192 and 215 microRNAs, which influence the response to pharmaceutical drugs against cancer of the colon, at the preclinical phase.

Psychiatric and cardiovascular diseases

Besides its application in cancer, pharmacogenetics is demonstrating its efficacy in other disciplines such as psychiatry. So today, more individualised treatment can be determined for psychotic disorders and epilepsy for each patient.

Another field that is growing fast is that involving the treatment of cardiovascular diseases. “One of the great risks of these illnesses is controlling the thrombotic processes involved in cerebrovascular accidents. The study of certain genes, such as ALOX5AP, can direct the most appropriate medication for each patient”, explained Dr. García-Foncillas.

In the opinion of the CIMA researcher, “the convergence of genetic and pharmacological studies has created a way for optimising both the treatment for each patient as well as health resources, given that we will be able to use pharmaceutical drugs in suitable doses, with fewer side effects and with patients that show better therapeutic response”.

Biokimika, Medikuntza, Osasuna Go to top of page
Additional information
Documents
Go to top of page

Search

Search in Basque Research [ Advanced search ]

Login

Users data

Navigation

Main menu

Go to top of page

Thesis Prize and International network

Go to top of page Go to top of page

Statistics

Go to top of page

XML RSS Feeds

Go to top of page

Standars and accesibility

Go to top of page

Register

Go to top of page

Menu for registered users

Go to top of page


BR Eraberritzen Bloga


Services

Go to top of page Go to top of page

Sponsors:

Eusko Jaurlaritza

The use of the contents of this website is forbidden without permission.

Copyright © 2007 Elhuyar Fundazioa

basqueresearch@elhuyar.com